Mild Behavioral Impairment and Plasma Biomarkers of Neurodegeneration as Predictors of Cognitive Decline in Geriatric Patients With Psychiatric Disorders

This is the authors' abstract. We don't add key points for this paper.

Background Mild Behavioral Impairment (MBI) has been increasingly recognized as a potential early clinical marker of neurodegenerative disease, while blood-based biomarkers such as phosphorylated tau 217 (p-tau217) and neurofilament light chain (NfL) are associated with Alzheimer’s disease and axonal damage, respectively. Objective To investigate the role of MBI and blood-based biomarkers of neurodegeneration in the early detection of dementia. Methods Fifty-one individuals without dementia aged 60 or older with mood or anxiety disorders underwent psychiatric, neuropsychiatric, and cognitive evaluations, as well as assessment of plasma p-tau217 and NfL at baseline and at one-year follow-up. Results A higher proportion of males was observed in the MBI group compared to the non-MBI group ( P = 0.076). MBI was significantly associated with a higher risk of conversion to dementia ( P = 0.006). MBI patients showed a trend toward higher baseline p-tau217 ( P = 0.096) and significantly higher NfL at follow-up ( P = 0.025), suggesting active neurodegeneration. Individuals who converted to dementia had marginally higher baseline p-tau217 ( P = 0.053) and NfL ( P = 0.091). Conclusion MBI and blood-based biomarkers of neurodegeneration appear to be promising clinical tools for identifying dementia risk in its early stages.